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Purpose: To evaluate risk factors associated with posterior subcapsular cataract (PSC) 
development and the relationship between vitamin D deficiency and etiology of PSC.
Methods: Of 195 consecutive patients from a private ophthalmology practice, diagnosed with 
PSC, serum vitamin D
3
 (25-OH D) levels were obtained for 175, and associations among risk 
factors, comorbidities, and PSC were assessed.
Results: In all 175 PSC patients, mean 25-OH D levels were low (24 ng/mL ±11 SD) com-
pared with age/sex-matched standards. Significant differences in 25-OH D levels were noted 
between PSC subjects taking/not taking calcium supplements, systemic steroids, osteoporosis 
medications, etc. Alone, smoking status and calcium channel blockers and/or topical steroids 
use made no significant difference in PSC subjects 25-OH D levels, but two or more of these 
factors were associated with lowered levels of 25-OH D (P,0.001). Low vitamin D was cor-
related with female sex, autoimmune disease, and non-skin cancer diagnosis, but not with age, 
or other comorbidities or medication use. In five early-stage PSC patients taking 5,000 IU of 
25-OH D daily for vitamin D deficiency, there was resolution of their cataracts during the 
2-year follow-up period.
Conclusion: Vitamin D levels for most PSC patients fell below the 30 ng/mL calcium homeo-
stasis threshold. Some comorbidities and non-ophthalmic interventions are associated with the 
development of PSC at less depressed levels of 25-OH D. In this series, vitamin D deficiency 
was associated with PSC cataract, suggesting that raising the level of vitamin D intake may 
reduce PSC incidence.
Keywords: posterior subcapsular, cataracts, vitamin D deficiency, risk factors, hypocalcemia, 
case report
Introduction
Posterior subcapsular cataract (PSC) is clinically common and known to be visually 
debilitating, having a high societal burden in terms of lost work and need for early 
surgical intervention. Prolonged corticosteroid use can lead to the development of 
PSC.1–3 Although other described risk factors4 include myopia,5 various skin disorders,6 
diabetes,7 intraocular inflammation or trauma,8 retinitis pigmentosa,9 and smoking,10 
the majority of PSCs have an unknown etiology.11 PSC resembles the hypocalcemic 
cataract described in the endocrine and veterinary literature, and can be reproduced 
in vitro or in vivo by incubating clear excised lenses in hypocalcemic media or by 
feeding animals diets deficient in calcium or in severe vitamin D deficiency states.12–16 
It was noted by one of the authors that within a large series of PSC cases, patients 
frequently presented with vitamin D insufficiency or deficiency. A retrospective 
examination of other risk factors was undertaken to establish any possible interactions 
with vitamin D deficiency as causative mechanisms of PSC formation, supporting the 
validity of the hypocalcemic animal model in humans.
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Methods
This study comprised 195 of 1,585 consecutive cataract 
patients seen in a private practice ophthalmology clinic 
between June 1, 2008 and June 1, 2010, and diagnosed with 
PSC/anterior subcapsular cataract (ASC) alone or mixed 
cataract PSC/ASC combined with nuclear or cortical opaci-
ties. Histories and risk factors were recorded by the senior 
author including steroid use, use of calcium supplements 
or osteoporosis medications, prior trauma, autoimmune or 
skin cancer disorders, diabetes, cancer diagnosis, or car-
diopulmonary disease. The use of concomitant medications 
for their control was taken from the chart record (Table 1). 
Levels of 25-OH D were obtained or available for 175 of 195 
PSC patients using either the DiaSorin LIAISON® Immu-
nochemiluminometric assay or the QuestAssureD™ liquid 
chromatography, tandem mass spectrometry. Both methods, 
Table 1 Patient demographics, cataract types, comorbidities, and 
risk factors
Demographics, 
cataract types,  
and risk factors
Total 
number  
of patients
Percentage 
of patients
Standard 
deviation
sex
Women 109 62.3
Men 66 37.7
age, years
,50 16 9
51–70 108 62
.71 51 29
Cataract components 
with PsC
asC 173 16 0.36
nuclear 175 95 0.22
Cortical 175 85 0.36
Concomitant medications
Ca2+ supplements 172 22 0.41
systemic steroids 175 25 0.43
Topical steroids 175 13 0.34
Ca2+ channel blockers 172 19 0.39
antidepressants 173 27 0.45
Osteoporosis drugs 173 9 0.28
Comorbidities, risk factors
Ocular trauma, prior 
surgery, inflammation
173 25 0.44
autoimmune disease 175 44 0.5
Cardiovascular disease 173 28 0.45
hypertension 173 53 0.5
asthma/COPD 173 9 0.28
non-skin cancer history 173 14 0.35
iDDM/niDDM 174 24 0.42
smoking history 165 20 0.40
retinitis pigmentosa 174 1 0.08
Abbreviations: PSC, posterior subcapsular cataract; ASC, anterior subcapsular 
cataract; COPD, chronic obstructive pulmonary disease; IDDM, insulin-dependent 
diabetes mellitus; NIDDM, non-insulin-dependent diabetes mellitus.
as performed by commercial laboratory testing services, had 
an analytical sensitivity of at least 4 ng/mL. Associations 
between risk factors and comorbidities and the presence of 
PSC were then assessed. A t-test for independent samples 
was used to determine whether the differences of 25-OH D 
levels in PSC subjects with and without risk factors and 
concomitant medications were statistically different from 
zero. In addition, a linear regression analysis was carried 
out to model the relationship between the level of 25-OH 
D and variables such as age, sex, autoimmune disease, 
hypertension, skin cancer, and antidepressant use. Access 
to anonymized clinical records by nonclinical personnel 
was approved by the Washington Regional Medical Center 
Institutional Review Board. All patients had received routine 
medical and surgical care. Patients whose cataracts inter-
fered with daily vision function were scheduled for cataract 
surgery. Those whose cataracts were minimally symptomatic 
or asymptomatic were followed without surgery. Patients 
in this interval of care newly diagnosed with low levels of 
vitamin D were treated and referred to their primary care 
physician for follow up. This was a retrospective chart 
review study, and all patients received routine care with no 
experimental intervention.
Results
All eyes were examined in the dilated state. Anterior and 
posterior subcapsular opacities were identified with the slit 
lamp set for retroillumination, spanning a range from axial 
retrodots to dense fibrotic plaques involving the capsule and 
immediately adjacent degenerating cortical lens fibers. In this 
study, all degrees of PSC and ASC were included. Lens Opac-
ity Classification System III17 grades P1–P5 represented the 
majority of subcapsular cataracts. Additionally, some PSCs 
were greater than P5, involving the entire posterior capsule, 
and some patients had predominantly anterior subcapsular 
opacities identical to posterior subcapsular opacities, except 
for anterior location and more severe functional visual dis-
turbance. Of 1,585 unique cataract patients seen during the 
study period, 12.3% had PSC (195/1,585), while 27.6% of 
patients who received cataract surgery had a PSC component 
(164/595). Vitamin D levels were evaluated for 175 (most 
bilateral; 62.3% female, 37.7% male; most were Caucasian) 
PSC patients (76% confirmed after diagnosis by serum test-
ing, 24% as lab values were obtained from history/referral 
chart). Mean 25-OH D level of PSC cataract patients was on 
the low normal end of the spectrum (24 ng/mL ± 11SD) com-
pared to age/sex-matched national standards for vitamin D 
levels.18 This serum 25-OH D level has been defined by some 
authorities as vitamin D insufficiency.19
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Significant differences in 25-OH D levels were noted 
between PSC subjects with and without certain risk factors 
and variables, including with or without calcium supplemen-
tation (28±11 vs 23±10 ng/mL; P=0.01), systemic steroids 
exposure (30±12 vs 22±9 ng/mL; P,0.001), or taking 
osteoporosis medications or not (28±14 vs 24±10 ng/mL; 
P=0.05) (Table 2). Smoking, use of calcium channel blockers, 
or topical steroid use alone showed no significant difference 
in 25-OH D levels between PSC patients with that variable 
or without it. However, marginally significant lower levels 
of vitamin D were noted when two or more variables were 
present compared with none of the variables (23±11 vs 
25±11 ng/mL; P=0.06) (Table 3). Linear regression analysis 
showed that 25-OH D levels also correlated with female 
sex (P=0.042), autoimmune disease (P,0.001), (non-skin) 
cancer diagnosis (P=0.016), but not with age, hypertension, 
eye trauma or inflammation (not shown), cardiopulmonary 
disease (not shown), diabetes (not shown), or antidepressant 
use (Table 4). Five patients with early-stage multiple axial 
posterior or anterior subcapsular water cleft cysts and retro 
dots who began taking 5,000 IU of vitamin D
3
 (25-OH D) 
daily, completely resolved their early-stage cataracts.
Discussion
Low vitamin D status is extremely common worldwide 
when the cut point of ,30–32 ng/mL is applied. In the USA, 
vitamin D levels have fallen over the last few decades due to 
fewer work and recreation-related outdoor activities, includ-
ing more air conditioning in homes and offices, television 
viewing, computer use, and intentional sun avoidance (ie, 
sun screen use).20 Milk fortification and dietary supplement 
have not closed the gap. The National Health and Nutrition 
Examination Surveys conducted between 1988 and 1994 
compared with those conducted between 2001 and 2006 
showed a mean decrease in age-specific 25-OH D levels of 
5–10 ng/mL for Caucasian men and 2–6 ng/mL for Cauca-
sian women. Other racial groups typically exhibited lower 
vitamin D levels even in the reference decades. Comorbidities 
on the rise due to lifestyle diseases or the aging demographic, 
including diabetic nephropathy and bone and mineral 
metabolism defects, may also be associated with vitamin D 
insufficiency or deficiency.21,22 Several agencies and guides 
now categorize serum 25-OH D levels ,10.0 ng/mL as 
very deficient with impaired bone mineralization (rickets/
osteomalacia), ,20 ng/mL as deficiency, 20–29 ng/mL as 
insufficiency, and above 30 ng/mL vitamin D as normal 
Table 2 Significantly different 25-OH vitamin D levels in PSC subjects with and without risk factors and concomitant medications
Variables Na Mean (ng/mL) P-value Standard deviation
all PsC 175 24 na 11
risk factors
PsC taking Ca2+ supplements 37 28 0.01 11
PsC not taking Ca2+ supplements 135 23 10
PsC taking systemic steroids 43 30 ,0.001 12
PsC not taking systemic steroids 132 22 9
PsC taking osteoporosis medications 15 28 0.05 14
PsC not taking osteoporosis medications 158 24 10
Notes: an,175 total. Information on all variables not available or not collected for all PSC subjects. Some patients declined to share their past medical histories or their 
current medications.
Abbreviation: PSC, posterior subcapsular cataract.
Table 3 Similar 25-OH vitamin D levels in PSC subjects with and without other risk factors and concomitant medications
Variables Na Mean (ng/mL) P-value Standard deviation
smoker PsCs 32 23 0.23 11
non-smoker PsCs 133 25 11
PsC taking topical steroids 23 23 0.30 10
PsC not taking topical steroids 152 24 11
PsC taking Ca2+ channel blockers 31 23 0.27 10
PsC not taking Ca2+ channel blockers 141 24 11
With one or more risk factors 74 23 0.06 11
Without one or more risk factors 90 25 11
Notes: an,175 total. Information on all variables not available or not collected for all PSC subjects. Some patients declined to share their past medical histories or their 
current medications.
Abbreviation: PSC, posterior subcapsular cataract.
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serum levels. The Institute of Medicine recently revised the 
Recommended Dietary Allowances of vitamin D in order 
to maintain serum 25-OH D at or above 50 nM (20 ng/mL) 
to sustain bone density and calcium absorption and minimize 
the risk of osteomalacia and rickets.23 But because vitamin D 
insufficiency seems to be associated with a number of adverse 
health effects, scientists and health professionals are advocat-
ing increasing vitamin D status to above 75 nM (30 ng/mL) 
25-OH D.24 Furthermore in a large cohort study, the association 
of serum 25-OH D levels with all-cause mortality was shown 
to be a nonlinear inverse association with risk increasing 
slightly at 25-OH D concentrations, ,75 nM (30 ng/mL) 
and was most strongly increased in subjects with vitamin D 
deficiency.25 In this series, the mean 25-OH D level for many 
more PSC patients was below this value (Figure 1).
Vitamin D is the chief regulator of systemic calcium 
as well as calcium levels in the serum and aqueous humor. 
Serum levels of vitamin D are negatively (P,0.01) corre-
lated with parathyroid (PTH). There is a stable plateau for 
serum PTH levels as long as serum 25-OH D levels remain 
above 31 ng/mL, but increase when 25-OH D levels drop 
below 31 ng/mL.26 Historic observations also suggest that 
PSC can be associated with PTH disorders.27,28 Disrup-
tion of calcium homeostasis in the lens has been shown 
experimentally to produce lens opacification via several 
mechanisms, including lens protein aggregation, enhanced 
migration of lens epithelial cells (LECs) onto the posterior 
capsule, abnormal differentiation of LECs into fibrocytes, 
lens fiber gap junction uncoupling, and loss of activity of 
calcium channels.29,30 Paradoxically, both hypocalcemia 
Table 4 Linear regression analysis of additional covariates associated with vitamin D levels in PSC subjects
25-OH D3 variable
a Coefficient of variation Standard error t-test value P-value 95% confidence interval
Constant 14.70876 4.834603 3.04 0.003 5.162234 24.25529
age 0.1325422 0.0748039 1.77 0.078 -0.0151675 0.2802519
sex 3.384471 1.651817 2.05 0.042 0.1227512 6.64619
autoimmunity -5.876174 1.631045 -3.60 ,0.001 -9.096875 2.655473
hypertension -3.978292 1.548215 -2.57 0.011 -7.035436 0.921148
non-skin cancer 5.08325 2.091757 2.43 0.016 0.952815 9.213685
antidepressant use 2.734565 1.626064 1.68 0.095 -0.4763008 5.945432
Notes: aExplanatory variables used in the regression include age expressed as a continuous variable expressed in the number of years; all others expressed as dummy variable 
that takes the value 1 if patient sex is male and 0 if female; or 1 with disease or medication characteristic or 0 without characteristic.
Abbreviation: PSC, posterior subcapsular cataract.
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Figure 1 individual PsC patient serum 25-Oh D3 levels and associated concomitant medications.
Notes: -- -- -- -- -- -- Mean vitamin D3 level, overall for 175 patients (24 ng/mL). --------- Individual subgroup means vitamin D3 levels. Ca
2+ supplements vs no Ca2+ supplements 
(P=0.01) and systemic steroids vs no systemic steroids (P,0.001). .............. Vitamin D insufficiency/deficiency level, Heaney and Holick recommendation24 (,30 ng/ml). 
__________ Vitamin D insufficiency/deficiency level, Institute of Medicine recommendation18,23 (,20–12 ng/ml).
Abbreviation: PSC, posterior subcapsular cataract.
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and hypercalcemia have been observed in association with 
experimental cataract models and in other forms of human 
cataract.31 It is possible that causative factors for PSC cata-
racts fall into a bimodal distribution pattern for vitamin D 
levels, where one class of PSC cataracts develops in subjects 
with 25-OH D levels above 28–32 ng/mL and the other in 
subjects with lower levels. The group with levels below 
28–32 ng/mL may have no other known risk factors for PCS 
except systemic hypocalcemia/low aqueous calcium. The 
group above ∼30 ng/mL may have known risk factors such 
as systemic steroid exposure, use of calcium supplements, 
or a need for osteoporosis medications.
PSC patients in the series reported here who were or had 
been using systemic steroids (but not topical steroids) showed 
a mean level of 25-OH D of 30 ng/mL, significantly higher 
than PSC subjects without systemic steroid exposure whose 
mean level was 22 ng/mL (Table 2 and Figure 1). Several 
studies have noted the association between the use of inhaled 
or oral corticosteroids and the long-term cataract risk.32 
Several cataractogenic mechanisms of action have been sug-
gested for steroids, including modulation of LEC migration33 
and downregulation of LEC fibroblast growth factor receptor 
and β-crystallin protein.32 LECs exhibit a steroid-binding 
membrane protein whose activities are mediated in part by 
calcium.34 Administration of a calcium-containing compound 
can reverse the cataract-inducing activity of steroids in an 
animal model.35 The failure to find an association between 
vitamin D levels in individuals with PSC, and comorbidities 
such as asthma and chronic obstructive pulmonary disease 
where steroid use would be expected, may be a result of 
their use of other management medications, insufficient 
duration of steroid use, or just a sample size limitation. The 
involvement of calcium signaling in PSC formation appears 
complex, given that individuals taking calcium supplements 
and osteoporosis medications appeared to have higher 25-OH 
D levels despite PSC formation. In the instance of patients 
on Ca2+ supplements, usually for incipient osteopenia or a 
diagnosis of osteoporosis, these supplements often include 
vitamin D in the formulation contributing to their elevated 
25-OH D level. It has been shown that as long as vitamin D 
levels are adequate, calcium intake need be no higher than 
800 mg/day36 for osteoporosis. Those taking calcium chan-
nel blockers had similar levels of vitamin D to those not 
using these medications. Because Ca2+ channel blockers are 
prescribed for hypertension, also not strongly correlated with 
vitamin D deficiency, this may also not be unexpected.
In the early stage of ASC and PSC, vitamin D deficiency 
affects the calcium metabolism of the LEC, causing cell junc-
tions to separate and creating cystic vacuoles that are visible 
as water cleft cysts. With time, the lens tissue becomes cloudy 
and distorted with calcium deposition; microscopically, the 
clear LECs turn into cloudy fibrocytes, eventually breaking 
down and depositing Ca2+ on the capsule forming white lens 
retrodots.37 In five patients in this series with evidence of early 
axial subcapsular water cleft cysts,38 their lenses unexpect-
edly normalized after taking 5,000 IU of vitamin D
3
 taken 
to treat their low vitamin D level.
Although 25-OH D is available in the human diet, it can 
also be synthesized from ultraviolet irradiation of 7-dehy-
droxycholesterol, a precursor present in mam malian skin. 
Following cutaneous production or intestinal absorption from 
nutritional sources, it is metabolized to 25-OH D
3
 in the liver 
by cytochrome P450 (CYP) 27A1. CYP27B1 in the kidney 
then converts this compound to the physiologically active 
hormone, 1α,25-dihydroxyvitamin D (calcitriol).39 Calcitriol 
binds to the intracellular vitamin D receptor (VDR), which 
heterodimerizes with retinoic X receptor and binds DNA. 
The protein transcription thus initiated regulates calcium 
metabolism. The gene for VDR has variant polymorphisms 
in a fraction of American population with various diseases.40 
Patients with the E420A mutant form of VDR are known 
to have vitamin D-resistant rickets, requiring vitamin D 
supplementation at doses up to 100,000 IU daily to maintain 
adequate blood levels.41 It is suspected that less severe forms 
of VDR impairment make it harder for some individuals to 
maintain adequate vitamin D
3
 levels without supplementation. 
It is hoped that with increasing and inexpensive gene testing 
methods, other haplotype VDR variations may be character-
ized to help identify patients who could benefit from additional 
vitamin D supplementation and thereby reduce their risk of 
PSC cataract formation and other allied disorders.
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